Business News • PR NewsWire • Positive Results From Human PK Study Assessing Orexo's New Intranasal Naloxone Formulations for Opioid Overdose Reversal

Positive Results From Human PK Study Assessing Orexo's New Intranasal Naloxone Formulations for Opioid Overdose Reversal

Positive Results From Human PK Study Assessing Orexo's New Intranasal Naloxone Formulations for Opioid Overdose Reversal

UPPSALA, Sweden, Jan. 7, 2019 /PRNewswire/ -- Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces positive results from the human pharmacokinetic (PK) study OX124-001 in 20 healthy volunteers, assessing Orexo's novel ...

View More : https://www.prnewswire.com:443/news-releases/positive-results-from-human-pk-study-assessing-orexos-new-intranasal-naloxo...

Releted News by prnewswire

Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs

Hexagon Strengthens Smart Factory Position With Autonomous Production Technologies From Etalon

IBM's Innovations at CES 2019 Showcase What's Next in Technology Transforming the World

IBM Earns Record 9,100 Patents in 2018, Tops U.S. Patent List